Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Baloxavir (S-033447) 是衍生自前药 Baloxavir marboxil,是流感病毒聚合酶 PA 亚基的一流帽依赖性核酸内切酶抑制剂。它抑制病毒 RNA 的转录和复制,具有强大的抗病毒活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 658 | 现货 | ||
5 mg | ¥ 1,550 | 现货 | ||
10 mg | ¥ 1,980 | 现货 | ||
25 mg | ¥ 3,530 | 现货 | ||
50 mg | ¥ 4,950 | 现货 | ||
100 mg | ¥ 6,950 | 现货 | ||
200 mg | ¥ 9,370 | 现货 | ||
500 mg | ¥ 13,900 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,650 | 现货 |
产品描述 | Baloxavir (S-033447) is a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit. |
体外活性 | Baloxavir (BXA) inhibits viral RNA transcription via selective inhibition of cap-dependent endonuclease (CEN) activity in enzymatic assays, and inhibits viral replication in infected cells without cytotoxicity in cytopathic effect assays, and it also inhibits cap-dependent endonuclease (CEN) and CEN/RdRp activities with IC50 values of 2.5 nM and 1.6 nM, respectively, while low potency (IC50 >40 nM) is observed against RdRp activity[2]. The median EC50 values at baseline for Baloxavir (BXA) are 17.96 nM for A/H1N1pdm, 4.48 nM for A/H3N2, and 18.67 nM for type B virus[1]. Baloxavir shows high potency against influenza A and B viruses with mean EC90 of 0.46 - 0.98 nM and 2.2-3.4 nM, respectively[2] and it also shows broad potency against various subtypes of influenza A viruses (H1N2, H5N1, H5N2, H5N6, H7N9 and H9N2). Additionally, serial passages of the viruses in the presence of Baloxavir result in isolation of PA/I38T variants with reduced BXA susceptibility[2]. Baloxavir (BXA) has a high inhibitory potency against CEN activity of the tested viral ribonucleoprotein complexes (vRNPs) from influenza A and B viruses with mean IC50 values of 1.4-3.1 nM and 4.5-8.9 nM, respectively, indicating that Baloxavir has broad spectrum activities. |
别名 | Baloxavir acid, S-033447 |
化合物与蛋白结合的复合物 |
The crystal structure of the 2009/H1N1/California PA endonuclease I38T (construct with truncated loop 51-72) in complex with baloxavir acid |
分子量 | 483.49 |
分子式 | C24H19F2N3O4S |
CAS No. | 1985605-59-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 47 mg/mL (97.21mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.0683 mL | 10.3415 mL | 20.683 mL | 51.7074 mL |
5 mM | 0.4137 mL | 2.0683 mL | 4.1366 mL | 10.3415 mL | |
10 mM | 0.2068 mL | 1.0341 mL | 2.0683 mL | 5.1707 mL | |
20 mM | 0.1034 mL | 0.5171 mL | 1.0341 mL | 2.5854 mL | |
50 mM | 0.0414 mL | 0.2068 mL | 0.4137 mL | 1.0341 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Baloxavir 1985605-59-1 Microbiology/Virology Influenza Virus inhibit CEN BXA cap-dependent dolutegravir S033447 influenza Baloxavir acid RNA replication S 033447 endonuclease S-033447 Inhibitor transcription inhibitor